Regulation of the metabolism of striatal dynorphin by the dopaminergic system

S. J. Li, Subbiah Sivam, J. F. McGinty, H. K. Jiang, J. Douglass, L. Calavetta, J. S. Hong

Research output: Contribution to journalArticle

87 Citations (Scopus)

Abstract

The purpose of this study was to explore the dopaminergic control of the striatonigral dynorphin system. Seven daily injections of a dopamine (DA) agonist, apomorphine (APO, 5 mg/kg, b.i.d., s.c.), caused a significant increase of dynorphin A (1-8)-like immunoreactivity (DN-LI) in the striatukm (140% over control) and substantia nigra (41% over control) without changing DN-LI in frontal cortex, hypothalamus and hippocampus. Immunocytochemistry revealed intense dynorphin A (1-17)-like immunostaining in striatal 'patch' neurons and striatonigral fibers after APO treatment. In order to understand the mechanism of increase in the peptide level, the abundance of preprodynorphin mRNA was quantified by Northern blot hybridization with a 32P-labeled cRNA probe coding for rat preprodynorphin. Seven daily injections of APO increased the abundance of striatal preprodynorphin mRNA by 60%. In another experiment, rats received a single injection of various doses of APO (0.5-2.5 mg/kg s.c.). Striatal DN-LI was decreased by 15% 1 hr after injection of a dose of 2.5 mg/kg of APO. Seven daily injections or a single injection of D-amphetamine produced effects similar to those elicited by APO. These studies reveal that the nigrostriatal DA system plays an important role in modulating the metabolism of striatonigral dynorphin-containing neurons.

Original languageEnglish (US)
Pages (from-to)403-408
Number of pages6
JournalJournal of Pharmacology and Experimental Therapeutics
Volume246
Issue number1
StatePublished - 1988
Externally publishedYes

Fingerprint

Corpus Striatum
Dynorphins
Injections
dynorphin (1-8)
Neurons
Complementary RNA
Messenger RNA
Apomorphine
Dopamine Agonists
Frontal Lobe
Substantia Nigra
Amphetamine
Northern Blotting
Hypothalamus
Hippocampus
Dopamine
Immunohistochemistry
Peptides
pre-prodynorphin

ASJC Scopus subject areas

  • Pharmacology

Cite this

Li, S. J., Sivam, S., McGinty, J. F., Jiang, H. K., Douglass, J., Calavetta, L., & Hong, J. S. (1988). Regulation of the metabolism of striatal dynorphin by the dopaminergic system. Journal of Pharmacology and Experimental Therapeutics, 246(1), 403-408.

Regulation of the metabolism of striatal dynorphin by the dopaminergic system. / Li, S. J.; Sivam, Subbiah; McGinty, J. F.; Jiang, H. K.; Douglass, J.; Calavetta, L.; Hong, J. S.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 246, No. 1, 1988, p. 403-408.

Research output: Contribution to journalArticle

Li, SJ, Sivam, S, McGinty, JF, Jiang, HK, Douglass, J, Calavetta, L & Hong, JS 1988, 'Regulation of the metabolism of striatal dynorphin by the dopaminergic system', Journal of Pharmacology and Experimental Therapeutics, vol. 246, no. 1, pp. 403-408.
Li, S. J. ; Sivam, Subbiah ; McGinty, J. F. ; Jiang, H. K. ; Douglass, J. ; Calavetta, L. ; Hong, J. S. / Regulation of the metabolism of striatal dynorphin by the dopaminergic system. In: Journal of Pharmacology and Experimental Therapeutics. 1988 ; Vol. 246, No. 1. pp. 403-408.
@article{d73538004d9d4b2da07fa1f0e266cf7a,
title = "Regulation of the metabolism of striatal dynorphin by the dopaminergic system",
abstract = "The purpose of this study was to explore the dopaminergic control of the striatonigral dynorphin system. Seven daily injections of a dopamine (DA) agonist, apomorphine (APO, 5 mg/kg, b.i.d., s.c.), caused a significant increase of dynorphin A (1-8)-like immunoreactivity (DN-LI) in the striatukm (140{\%} over control) and substantia nigra (41{\%} over control) without changing DN-LI in frontal cortex, hypothalamus and hippocampus. Immunocytochemistry revealed intense dynorphin A (1-17)-like immunostaining in striatal 'patch' neurons and striatonigral fibers after APO treatment. In order to understand the mechanism of increase in the peptide level, the abundance of preprodynorphin mRNA was quantified by Northern blot hybridization with a 32P-labeled cRNA probe coding for rat preprodynorphin. Seven daily injections of APO increased the abundance of striatal preprodynorphin mRNA by 60{\%}. In another experiment, rats received a single injection of various doses of APO (0.5-2.5 mg/kg s.c.). Striatal DN-LI was decreased by 15{\%} 1 hr after injection of a dose of 2.5 mg/kg of APO. Seven daily injections or a single injection of D-amphetamine produced effects similar to those elicited by APO. These studies reveal that the nigrostriatal DA system plays an important role in modulating the metabolism of striatonigral dynorphin-containing neurons.",
author = "Li, {S. J.} and Subbiah Sivam and McGinty, {J. F.} and Jiang, {H. K.} and J. Douglass and L. Calavetta and Hong, {J. S.}",
year = "1988",
language = "English (US)",
volume = "246",
pages = "403--408",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "1",

}

TY - JOUR

T1 - Regulation of the metabolism of striatal dynorphin by the dopaminergic system

AU - Li, S. J.

AU - Sivam, Subbiah

AU - McGinty, J. F.

AU - Jiang, H. K.

AU - Douglass, J.

AU - Calavetta, L.

AU - Hong, J. S.

PY - 1988

Y1 - 1988

N2 - The purpose of this study was to explore the dopaminergic control of the striatonigral dynorphin system. Seven daily injections of a dopamine (DA) agonist, apomorphine (APO, 5 mg/kg, b.i.d., s.c.), caused a significant increase of dynorphin A (1-8)-like immunoreactivity (DN-LI) in the striatukm (140% over control) and substantia nigra (41% over control) without changing DN-LI in frontal cortex, hypothalamus and hippocampus. Immunocytochemistry revealed intense dynorphin A (1-17)-like immunostaining in striatal 'patch' neurons and striatonigral fibers after APO treatment. In order to understand the mechanism of increase in the peptide level, the abundance of preprodynorphin mRNA was quantified by Northern blot hybridization with a 32P-labeled cRNA probe coding for rat preprodynorphin. Seven daily injections of APO increased the abundance of striatal preprodynorphin mRNA by 60%. In another experiment, rats received a single injection of various doses of APO (0.5-2.5 mg/kg s.c.). Striatal DN-LI was decreased by 15% 1 hr after injection of a dose of 2.5 mg/kg of APO. Seven daily injections or a single injection of D-amphetamine produced effects similar to those elicited by APO. These studies reveal that the nigrostriatal DA system plays an important role in modulating the metabolism of striatonigral dynorphin-containing neurons.

AB - The purpose of this study was to explore the dopaminergic control of the striatonigral dynorphin system. Seven daily injections of a dopamine (DA) agonist, apomorphine (APO, 5 mg/kg, b.i.d., s.c.), caused a significant increase of dynorphin A (1-8)-like immunoreactivity (DN-LI) in the striatukm (140% over control) and substantia nigra (41% over control) without changing DN-LI in frontal cortex, hypothalamus and hippocampus. Immunocytochemistry revealed intense dynorphin A (1-17)-like immunostaining in striatal 'patch' neurons and striatonigral fibers after APO treatment. In order to understand the mechanism of increase in the peptide level, the abundance of preprodynorphin mRNA was quantified by Northern blot hybridization with a 32P-labeled cRNA probe coding for rat preprodynorphin. Seven daily injections of APO increased the abundance of striatal preprodynorphin mRNA by 60%. In another experiment, rats received a single injection of various doses of APO (0.5-2.5 mg/kg s.c.). Striatal DN-LI was decreased by 15% 1 hr after injection of a dose of 2.5 mg/kg of APO. Seven daily injections or a single injection of D-amphetamine produced effects similar to those elicited by APO. These studies reveal that the nigrostriatal DA system plays an important role in modulating the metabolism of striatonigral dynorphin-containing neurons.

UR - http://www.scopus.com/inward/record.url?scp=0023762608&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023762608&partnerID=8YFLogxK

M3 - Article

C2 - 2899169

AN - SCOPUS:0023762608

VL - 246

SP - 403

EP - 408

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 1

ER -